Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR 1,253.60
-17.45 (-1.37%)
At close: Jan 1, 2026
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 88.28B INR in the quarter ending September 30, 2025, with 9.83% growth. This brings the company's revenue in the last twelve months to 343.10B, up 14.13% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
343.10B
Revenue Growth
+14.13%
P/S Ratio
3.05
Revenue / Employee
12.30M
Employees
27,811
Market Cap
1.04T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -15.09B | -23.18% |
| Mar 31, 2007 | 65.10B | 40.83B | 168.24% |
| Mar 31, 2006 | 24.27B | 4.75B | 24.32% |
| Mar 31, 2005 | 19.52B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
Dr. Reddy's Laboratories News
- 2 days ago - Dr Reddy, Cipla, Sun Pharma and other stocks in focus today as Govt bans high-dose Nimesulide formulations - Business Upturn
- 8 days ago - Nifty 50 top losers today, December 24: IndiGo, Dr. Reddy’s, Wipro, Adani Enterprises, HDFC Life, Tata Motors PV and more - Business Upturn
- 9 days ago - Dr Reddy’s Laboratories shares in focus as company’s semaglutide not approved in Canada – Know More - Business Upturn
- 9 days ago - Dr Reddy’s semaglutide not approved in Canada as Health Canada flags regulatory gaps: Report - Business Upturn
- 20 days ago - Dr. Reddy’s Laboratories receives five observations following USFDA inspection at Srikakulam facility - Business Upturn
- 21 days ago - Dr. Reddy’s Laboratories announces SBTi-approved Net Zero targets for FY2045 - Business Upturn
- 23 days ago - Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's - Nasdaq
- 25 days ago - Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa - Business Upturn